1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  11:30 2022-08-16 am EDT
80.98 CHF   +0.66%
08/15European Stocks Edge Up Despite Continued Eurozone Recession Fears
MT
08/15GLOBAL MARKETS LIVE : Prada, Koh'ls, Alphabet, Meta, Novartis...
MS
08/15Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis Gets Positive Opinion from EU Medicines Agency Committee for Chronic Myeloid Leukemia Drug

06/24/2022 | 07:39am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG 0.66% 80.98 Delayed Quote.0.21%
PFIZER, INC. -0.08% 49.6839 Delayed Quote.-15.75%
All news about NOVARTIS AG
08/15European Stocks Edge Up Despite Continued Eurozone Recession Fears
MT
08/15GLOBAL MARKETS LIVE : Prada, Koh'ls, Alphabet, Meta, Novartis...
MS
08/15Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
MT
08/15HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in..
CI
08/15Novartis' Phase 3 Lung Cancer Drug Trial Fails to Meet Primary Endpoint; Shares Down Pr..
MT
08/15Novartis fails again to reuse anti-inflammatory drug to treat lung cancer
RE
08/15Novartis' Lung Cancer Drug Fails to Extend Patient Survival in Late-stage Study
MT
08/15Novartis says lung cancer drug canakinumab failed phase III trial
RE
08/15Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant..
GL
08/15Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant..
DJ
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 52 230 M - -
Net income 2022 9 119 M - -
Net Debt 2022 8 363 M - -
P/E ratio 2022 21,3x
Yield 2022 3,91%
Capitalization 186 B 186 B -
EV / Sales 2022 3,72x
EV / Sales 2023 3,58x
Nbr of Employees 108 000
Free-Float 87,0%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 85,14 $
Average target price 96,18 $
Spread / Average Target 13,0%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG0.21%185 841
JOHNSON & JOHNSON-2.91%436 680
ELI LILLY AND COMPANY13.66%298 298
PFIZER, INC.-15.75%279 215
ROCHE HOLDING AG-16.14%277 502
ABBVIE INC.5.09%251 582